BBP-418 (ribitol)

DRUG2 trials

Sponsors

ML Bio Solutions, Inc.

Conditions

Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)

Phase 3

Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)

Active, not recruitingNCT05775848

ML Bio Solutions, Inc.Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)

Start: 2023-05-31End: 2027-09-01Updated: 2026-09-09

Open-Label Extension Study of BBP-418 (Ribitol) for LGMD2I/R9

Active, not recruitingNCT07678775

ML Bio Solutions, Inc.Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)

Start: 2026-06-05End: 2030-10-01Target: 107Updated: 2026-07-02